Product image of Kaliumfosfaat B. Braun (Dipotassium Phosphate, Potassium Dihydrogen Phosphate) supplied by GNH India

Kaliumfosfaat B. Braun

Active Ingredient:
Dipotassium Phosphate, Potassium Dihydrogen Phosphate
Origin:
EU

Kaliumfosfaat B. Braun (Dipotassium Phosphate, Potassium Dihydrogen Phosphate)

Dipotassium Phosphate, the active ingredient in Kaliumfosfaat B. Braun, is an electrolyte presented as an injection solution for intravenous use. It treats hypophosphatemia, hypokalemia and provides electrolyte replacement in patients requiring correction of potassium and phosphate deficits.

GNH India supplies Kaliumfosfaat B. Braun as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

B.Braun Melsungen Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Kaliumfosfaat B. Braun is used in the management of electrolyte disorders, particularly those involving phosphate and potassium deficits.

  • Hypophosphatemia: restores serum phosphate levels and supports cellular energy metabolism.
  • Hypokalemia: supplies potassium ions to correct low serum potassium and prevent cardiac arrhythmias.
  • Electrolyte replacement therapy: provides combined potassium and phosphate ions for patients undergoing surgery, trauma or renal replacement therapy.

How It Works

  • The injection delivers dipotassium phosphate and potassium dihydrogen phosphate directly into the bloodstream, releasing potassium and phosphate ions. These ions replenish intracellular and extracellular stores, correct electrolyte imbalances, and support enzymatic processes that depend on phosphate, such as ATP synthesis and cellular signaling pathways.

Side Effects

Kaliumfosfaat B. Braun may be associated with adverse reactions following intravenous administration.

Common Side Effects

  • Local irritation at the infusion site.
  • Mild nausea or vomiting.
  • Transient headache.
  • Mild hyperkalemia (elevated serum potassium).
  • Mild hyperphosphatemia (elevated serum phosphate).

Serious or Rare Side Effects

  • Severe hyperkalemia leading to cardiac arrhythmia.
  • Severe hyperphosphatemia causing calcium-phosphate precipitation.
  • Allergic reactions including rash, urticaria, or anaphylaxis.
  • Metabolic acidosis.
  • Vascular thrombosis at the infusion site.

Precautions & Warnings

When using Kaliumfosfaat B. Braun, clinicians should consider several safety measures.

  • Renal function: assess kidney function before administration, as impaired excretion can exacerbate hyperkalemia.
  • Cardiac status: monitor ECG in patients with existing cardiac disease or electrolyte disturbances.
  • Serum electrolytes: check baseline potassium and phosphate levels and re‑measure after infusion.
  • Infusion rate: administer at the prescribed rate to avoid rapid shifts in serum concentrations.
  • Compatibility: verify compatibility with other IV solutions before mixing.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Kaliumfosfaat B. Braun can interact with other medications that affect electrolyte balance or cardiac conduction.

Major Interactions (Avoid)

  • ACE inhibitors or ARBs: may potentiate hyperkalemia.
  • Potassium‑sparing diuretics (e.g., spironolactone): increase risk of severe hyperkalemia.
  • Sodium bicarbonate: can precipitate calcium phosphate when combined.

Moderate Interactions (Monitor Closely)

  • Digoxin: altered potassium levels can affect digoxin toxicity.
  • Calcium channel blockers: monitor for additive cardiac effects.
  • Insulin or beta‑agonists: may shift potassium intracellularly, requiring electrolyte monitoring.

Frequently Asked Questions

Kaliumfosfaat B. Braun is an intravenous potassium phosphate injection used to correct low blood levels of phosphate and potassium. It is indicated for hypophosphatemia, hypokalemia, and general electrolyte replacement in patients who need rapid restoration of these essential ions.

Dipotassium phosphate dissociates after intravenous administration, releasing potassium and phosphate ions. These ions replenish intracellular and extracellular stores, support ATP production, and help maintain acid‑base balance, thereby correcting electrolyte disturbances and supporting normal cellular function.

The specific dose of Kaliumfosfaat B. Braun is determined by the prescribing clinician based on the patient’s serum electrolyte levels, renal function, and clinical condition. Dosage is individualized and administered under medical supervision.

Safety data for Kaliumfosfaat B. Braun in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Kaliumfosfaat B. Braun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and import documentation.

Kaliumfosfaat B. Braun provides a combined source of potassium and phosphate in a single intravenous formulation, which can be more convenient than administering separate potassium chloride and phosphate solutions. It offers rapid correction of both deficits, whereas oral supplements act more slowly and may be less suitable for acute correction.

Kaliumfosfaat B. Braun should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain stability and sterility.

The product is administered intravenously by a qualified healthcare professional. It is typically given as an infusion over a prescribed period, with the rate and volume determined by the clinician based on the patient’s electrolyte status and clinical needs.

The most serious risks include severe hyperkalemia, which can cause cardiac arrhythmias, and severe hyperphosphatemia, which may lead to calcium‑phosphate precipitation and tissue damage. Monitoring serum electrolytes and cardiac function during therapy is essential to mitigate these risks.

Patients with known hypersensitivity to potassium phosphate preparations, severe renal impairment, uncontrolled hyperkalemia, or those receiving medications that significantly raise potassium levels should not receive Kaliumfosfaat B. Braun unless a clinician determines it is absolutely necessary.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Dipotassium Phosphate, Potassium Dihydrogen Phosphate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT